Page last updated: 2024-10-23

benserazide and Lennox Gastaut Syndrome

benserazide has been researched along with Lennox Gastaut Syndrome in 1 studies

Benserazide: An inhibitor of DOPA DECARBOXYLASE that does not enter the central nervous system. It is often given with LEVODOPA in the treatment of parkinsonism to prevent the conversion of levodopa to dopamine in the periphery, thereby increasing the amount that reaches the central nervous system and reducing the required dose. It has no antiparkinson actions when given alone.
benserazide : A carbohydrazide that results from the formal condensation of the carboxy group of DL-serine with the primary amino group of 4-(hydrazinylmethyl)benzene-1,2,3-triol. An aromatic-L-amino-acid decarboxylase inhibitor (DOPA decarboxylase inhibitor) that does not enter the central nervous system, it is used as its hydrochloride salt as an adjunct to levodopa in the treatment of parkinsonism. By preventing the conversion of levodopa to dopamine in the periphery, it causes an increase in the amount of levodopa reaching the central nervous system and so reduces the required dose. Benserazide has no antiparkinson actions when given alone.

Lennox Gastaut Syndrome: A childhood-onset epilepsy syndrome.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Hodoba, D1
Santic, AM1
Schmidt, D1

Other Studies

1 other study available for benserazide and Lennox Gastaut Syndrome

ArticleYear
Adjunctive Madopar for ultrarefractory epilepsy? Preliminary observations.
    Epilepsy & behavior : E&B, 2013, Volume: 28, Issue:2

    Topics: Adult; Anticonvulsants; Benserazide; Brain Injuries; Drug Combinations; Enzyme Inhibitors; Epilepsy;

2013
chemdatabank.com